GlassScriptPhysician profile
Rammurti Kamble
NPI 1073693339
$11,619.26
in general payments reported to CMS, 2019-2025
29 companies · $2,765 in 2025
The $2,765 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,877 · 2020: $157 · 2021: $3,781 · 2022: $450 · 2023: $590 · 2025: $2,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,965 · Food and Beverage: $328 · Travel and Lodging: $61.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,965.00 |
| Food and Beverage | $328.40 |
| Travel and Lodging | $61.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,223.15 | 2019-2021 | |
| Janssen Biotech, INC. | $1,854.73 | 2019-2025 | Darzalex |
| Kite Pharma, INC. | $1,729.31 | 2021-2025 | Yescarta |
| Genzyme Corporation | $1,438.65 | 2019-2021 | |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Beigene, LTD. | $590.00 | 2023 | Brukinsa |
| Astellas Pharma US INC | $521.69 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $429.15 | 2019-2022 | |
| Becton, Dickinson and Company | $200.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $150.00 | 2025 | Talvey |
| Novartis Pharmaceuticals Corporation | $111.47 | 2019-2020 | |
| Glaxosmithkline, LLC. | $100.00 | 2021 | |
| Amgen INC. | $85.51 | 2019-2020 | |
| Gilead Sciences, INC. | $80.13 | 2025 | |
| Celgene Corporation | $76.20 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $64.75 | 2019-2025 | Ninlaro |
| Incyte Corporation | $62.45 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.30 | 2019 | |
| Pfizer INC. | $34.58 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $31.80 | 2019 | |
| Amag Pharmaceuticals, INC. | $26.03 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.81 | 2025 | Lynozyfic |
| Rigel Pharmaceuticals, INC. | $16.24 | 2019 | |
| Adaptive Biotechnologies Corporation | $16.05 | 2025 | Clonoseq |
| Agios Pharmaceuticals, INC. | $14.98 | 2019 | |
| Seagen INC. | $14.14 | 2019 | |
| Dova Pharmaceuticals | $13.80 | 2019 | |
| Array Biopharma INC | $12.69 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rammurti Kamble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.